{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zanubrutinib+80+MG", "query": { "intervention": "Zanubrutinib 80 MG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zanubrutinib+80+MG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T06:35:03.437Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03465059", "title": "Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Insufficiency & Healthy Subjects" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2018-05-30", "completion_date": "2018-10-19", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 2, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03465059" }, { "nct_id": "NCT04277637", "title": "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature B-Cell Malignancies" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2020-03-24", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 13, "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04277637" }, { "nct_id": "NCT04382586", "title": "Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Pulmonary Complications", "COVID-19" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Supportive Care", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2020-07-06", "completion_date": "2021-02-01", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 10, "location_summary": "Fullerton, California • Washington D.C., District of Columbia • Thomasville, Georgia + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Thomasville", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04382586" }, { "nct_id": "NCT06846463", "title": "Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "DLBCL - Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2025-05-27", "completion_date": "2032-07-31", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846463" }, { "nct_id": "NCT03301181", "title": "Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers: Asian, Non-Asian" ], "interventions": [ { "name": "BGB-3111 (Arm A)", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "BGB-3111 (Arm B)", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2017-09-18", "completion_date": "2017-11-13", "has_results": false, "last_update_posted_date": "2019-11-01", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03301181" }, { "nct_id": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-10-31", "completion_date": "2027-10-31", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 18, "location_summary": "Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336333" }, { "nct_id": "NCT03846427", "title": "Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma", "MZL" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2019-02-19", "completion_date": "2022-05-04", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 2, "location_summary": "Westbury, New York • Charlotte, North Carolina", "locations": [ { "city": "Westbury", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03846427" }, { "nct_id": "NCT05100862", "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 799, "start_date": "2022-03-10", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 50, "location_summary": "Fresno, California • Irvine, California • Los Alamitos, California + 43 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05100862" }, { "nct_id": "NCT02914938", "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Follicular Lymphoma (FL)", "Marginal Zone B Cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "High Grade Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma (MCL)" ], "interventions": [ { "name": "ME-401", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEI Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2016-10", "completion_date": "2023-03-29", "has_results": false, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 23, "location_summary": "Tucson, Arizona • Corona, California • Miami, Florida + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914938" }, { "nct_id": "NCT04163783", "title": "Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "[14C]-BGB-3111", "type": "DRUG" }, { "name": "BGB-3111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2017-03-29", "completion_date": "2017-04-18", "has_results": false, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-09-30T06:35:03.437Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04163783" } ] }